IBTK and myeloid sarcoma: Among potentially relevant BTKi targets for impacting progressive disease in MS are B-cell rich meningeal immune-cell infiltrates which also contain myeloid cells, T cells and stromal cells [53] and are associated with adjacent sites of subpial cortical demyelination and neuronal loss, linked with progressive disease [22, 35, 53].